Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions
Journal of Allergy and Clinical Immunology · 2023-02 · 151 (2) · 289-300.e4
DOI: 10.1016/j.jaci.2022.12.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-02. Verfasst von Andrew Gibson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia. Hauptthemen laut MEDLINE: Drug Hypersensitivity Syndrome, Stevens-Johnson Syndrome, Eosinophilia. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHGRI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome, toxic epidermal necrolysis (SJS/TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS) cause significant morbidity and mortality and impede new drug development. HLA class I associations with SJS/TEN and drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome have aided preventive efforts and provided insights into immunopathogenesis. In SJS/TEN, HLA class I-restricted oligoclonal CD8+ T-cell responses occur at the tissue level. However, specific HLA risk allele(s) and antigens driving this response have not been identified for most drugs. HLA risk alleles also have incomplete positive and negative predictive values, making truly comprehensive screening currently challenging. Although, there have been key paradigm shifts in knowledge regarding drug hypersensitivity, there are still many open and unanswered questions about SCAR immunopathogenesis, as well as genetic and environmental risk. In addition to understanding the cellular and molecular basis of SCAR at the single-cell level, identification of the MHC-restricted drug-reactive self- or viral peptides driving the hypersensitivity reaction will also be critical to advancing premarketing strategies to predict risk at an individual and drug level. This will also enable identification of biologic markers for earlier diagnosis and accurate prognosis, as well as drug causality and targeted therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tenn.
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.
- Department of Dermatology, Vanderbilt University Medical Center, Nashville; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn.
- Dokumentationszentrum schwerer Hautreaktionen Department of Dermatologie, Medical Center and Medical Faculty, University of Freiburg, Freiberg, Germany.
- Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Förderung
- NIAID NIH HHS
- NHGRI NIH HHS
- NHLBI NIH HHS
- NIAMS NIH HHS
- Medical Research Council
Zitieren
APA
Gibson, A., Deshpande, P., Campbell, C. N., Krantz, M. S., Mukherjee, E., Mockenhaupt, M., Pirmohamed, M., Palubinsky, A. M., & Phillips, E. J. (2023). Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. Journal of Allergy and Clinical Immunology, 151(2), 289-300.e4. https://doi.org/10.1016/j.jaci.2022.12.005
Vancouver
Gibson A, Deshpande P, Campbell CN, Krantz MS, Mukherjee E, Mockenhaupt M, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. Journal of Allergy and Clinical Immunology. 2023;151(2):289-300.e4. doi:10.1016/j.jaci.2022.12.005
BibTeX
@article{Gibson2023,
author = {Gibson, Andrew and Deshpande, Pooja and Campbell, Chelsea N and Krantz, Matthew S and Mukherjee, Eric and Mockenhaupt, Maja and Pirmohamed, Munir and Palubinsky, Amy M and Phillips, Elizabeth J},
title = {Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
volume = {151},
number = {2},
pages = {289--300.e4},
doi = {10.1016/j.jaci.2022.12.005}
}
EUVIMED